What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

December 8, 2025Blood

Efficacy of tocilizumab prophylaxis in preventing cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome: A systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

MSMoazzam ShahzadUniversity of South Florida AZAnas ZayadHamad Medical Corporation RPRohan ParvathalaKansas City University

Discussion

Member takes

Implication

Systematic review demonstrates the efficacy of tocilizumab in reducing cytokine release syndrome among CAR-T patients, suggesting its preventive role.

Key Points

Tocilizumab prophylaxis significantly reduces the incidence of cytokine release syndrome and ICANS in CAR-T therapy.
Pooled rates show a 28% incidence of CRS and a 14% incidence of ICANS among 430 patients analyzed in this meta-analysis.
Comprehensive evaluation includes 11 studies, applying a random-effects model to establish confidence intervals for outcomes.
Findings indicate potential for tocilizumab in managing adverse effects of CAR-T therapy, highlighting the need for further randomized trials.

Cite This Study

Shahzad et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d619 https://doi.org/10.1182/blood-2025-7602

View Full Paper

Ask AI

Bookmark

Implication

Systematic review demonstrates the efficacy of tocilizumab in reducing cytokine release syndrome among CAR-T patients, suggesting its preventive role.